SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients by Kumar, P et al.
POSTER PRESENTATION Open Access
SUPPORT: 48-week results of fosamprenavir/
ritonavir vs efavirenz with abacavir/lamivudine in
under-represented, antiretroviral-naïve patients
P Kumar
1, E DeJesus
2, G Huhn
3, L Sloan
4, F Garcia
5, C Small
6, H Edelstein
7, F Felizarta
8, R Hao
9,BH a
10*, B Stancil
10,
L Ross
10, K Oie
10, K Pappa
10
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Purpose of study
The objective of this study was to evaluate the efficacy,
tolerability, and safety of fosamprenavir/ritonavir (FPV/r)
versus efavirenz (EFV), both in combination with abaca-
vir/lamivudine (ABC/3TC), in a population that is often
underrepresented in U.S. clinical trials.
Methods
In this ongoing 96-week, open-label, prospective, rando-
mized, multicenter study, we compared once-daily ABC/
3TC 600 mg/300 mg with FPV 1400 mg/r 100 mg or EFV
600 mg in ARV-naïve, HIV-1-infected subjects with entry
viral load (VL) >5,000 c/mL, were HLA-B*5701 negative,
and did not have major resistance mutations to study
drugs. The primary endpoint was time to switch of third
drug or time to development of any treatment-related
Grade 3 or 4 adverse events (AEs). Results from the
planned 48-week analysis are reported.
Summary of results
SUPPORT enrolled 32% (32/101) women and 79% (80/
101) non-Caucasians. Baseline and demographic charac-
teristics were generally similar between groups. A total of
84 subjects (83%) completed study through W48. Eight
patients met the primary endpoint: 3 (6%) and 5 (10%) on
FPV/r and EFV, respectively. At W48, by ITT-Exposed
missing-equals-failure analysis, 76% (39/51) and 82% (41/
50) of subjects achieved VL <50 c/mL on FPV/r vs. EFV,
respectively. Median change from baseline to W48 in CD4
cell count was 178 cells/mm
3 in each group. Rate of treat-
ment-related grade 2-4 AEs was lower in the FPV/r-arm
(9/51, 18%) vs. the EFV-arm (15/50, 30%) primarily due to
EFV-related rash and dizziness (8% each). Rates of treat-
ment-related serious AEs and grade 3-4 lab abnormalities
were similar between FPV/r vs. EFV. A total of 8 virologic
failures occurred through W48. At failure, HIV PRO or
RT treatment-emergent mutations were present in 4 of 5
EFV patients and 1 of 3 FPV/r patients selected an RT
mutation. Median change from BL in total/HDL choles-
terol ratio was unchanged in both groups but the FPV/r
arm had larger changes in triglycerides (32 vs. 7 mg/dL)
and in LDL cholesterol (22 vs. 11 mg/dL).
Conclusions
Through 48 weeks, in a diverse population, virologic/
immunologic responses were not demonstrably different
between FPV/r and EFV when given with ABC/3TC, but
the EFV regimen had slightly more patients meeting the
tolerability endpoint, treatment-related grade 2-4 AEs, viro-
logic failures, and treatment-emergent mutations at failure.
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